Nisa Investment Advisors
BCRX icon

Nisa Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nisa Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.1K Buy
3,109
+706
+29% +$6.38K ﹤0.01% 2048
2026
Q1 		$22.9K Sell
2,403
-154
-6% -$1.2K ﹤0.01% 1958
2025
Q4 		$19.9K Sell
2,557
-265
-9% -$1.92K ﹤0.01% 1940
2025
Q3 		$21.4K Hold
2,822
– – ﹤0.01% 1963
2025
Q2 		$25.3K Buy
2,822
+34
+1% +$317 ﹤0.01% 1828
2025
Q1 		$20.9K Buy
2,788
+294
+12% +$2.37K ﹤0.01% 1854
2024
Q4 		$18.8K Sell
2,494
-75
-3% -$569 ﹤0.01% 1955
2024
Q3 		$19.5K Buy
2,569
+476
+23% +$3.62K ﹤0.01% 1916
2024
Q2 		$12.9K Buy
2,093
+3
+0.1% +$17 ﹤0.01% 2071
2024
Q1 		$10.6K Buy
2,090
+180
+9% +$1.01K ﹤0.01% 2026
2023
Q4 		$11.4K Sell
1,910
-3,415
-64% -$19.8K ﹤0.01% 2014
2023
Q3 		$37.7K Buy
5,325
+34
+0.6% +$244 ﹤0.01% 1812
2023
Q2 		$37.2K Buy
5,291
+3,371
+176% +$27.1K ﹤0.01% 1852
2023
Q1 		$16K Sell
1,920
-4,430
-70% -$42.6K ﹤0.01% 2064
2022
Q4 		$73K Buy
6,350
+11
+0.2% +$137 ﹤0.01% 1658
2022
Q3 		$85K Buy
6,339
+129
+2% +$1.66K ﹤0.01% 1559
2022
Q2 		$66K Hold
6,210
– – ﹤0.01% 1638
2022
Q1 		$101K Sell
6,210
-730
-11% -$11.7K ﹤0.01% 1612
2021
Q4 		$107K Sell
6,940
-4,560
-40% -$60.3K ﹤0.01% 1493
2021
Q3 		$165K Hold
11,500
– – ﹤0.01% 1481
2021
Q2 		$182K Sell
11,500
-425
-4% -$5.77K ﹤0.01% 1441
2021
Q1 		$121K Buy
11,925
+9,000
+308% +$92.8K ﹤0.01% 1667
2020
Q4 		$22K Buy
2,925
+850
+41% +$4.38K ﹤0.01% 2103
2020
Q3 		$7K Hold
2,075
– – ﹤0.01% 2160
2020
Q2 		$10K Buy
2,075
+105
+5% +$419 ﹤0.01% 1916
2020
Q1 		$4K Buy
+1,970
New +$5.42K ﹤0.01% 1968
2017
Q2 		– Sell
-1,000
Closed -$8K – 1837
2017
Q1 		$8K Buy
+1,000
New +$6.96K ﹤0.01% 1724
2016
Q2 		– Sell
-2,600
Closed -$7K – 1861
2016
Q1 		$7K Buy
+2,600
New +$11.5K ﹤0.01% 1814

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Nisa Investment Advisors's BCRX Position: Q2 2026 in Review

Nisa Investment Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 29% in Q2 2026, buying an estimated $6.38K and bringing the position to 3,109 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2048.

Nisa Investment Advisors first reported a position in BCRX in Q1 2016 and has held it in 28 quarters since. The position peaked at $182K in Q2 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Nisa Investment Advisors held 3,109 shares of BioCryst Pharmaceuticals worth $31.1K as of Q2 2026.
  • Nisa Investment Advisors bought 706 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $6.38K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2048 holding.
  • Nisa Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2016 and has held it in 28 quarters since.
  • Nisa Investment Advisors's BioCryst Pharmaceuticals position peaked at $182K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.